Apogee Therapeutics Inc.
IPO Year: 2023
Exchange: NASDAQ
Recent Analyst Ratings for Apogee Therapeutics Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $95.00 | Buy | Citigroup |
| 11/25/2024 | $89.00 | Buy | Canaccord Genuity |
| 5/10/2024 | $80.00 | Buy | BofA Securities |
| 12/20/2023 | $43.00 | Buy | BTIG Research |
| 8/8/2023 | Outperform | TD Cowen | |
| 8/8/2023 | $40.00 | Outperform | Wedbush |
| 8/8/2023 | $29.00 | Buy | Guggenheim |
| 8/8/2023 | $34.00 | Buy | Stifel |
| 8/8/2023 | $29.00 | Buy | Jefferies |
Apogee Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by positive APG990 interim Phase 1 results, which exceeded trial objectives and demonstrated potential for three- and six-month dosing in combination with APG777; APG279 readout expected in second half of 2026 $731.1 million cash, cash equivalents and marketable securities with runway into Q1 2028 SAN FRANCISCO and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company ad
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by successful completion of preclinical combination toxicology studies and positive APG990 interim Phase 1 results; trial planned to initiate this year with readout expected in second half of 2026 Webcast to be held today at 8:30 a.m. ET SAN FRANCISCO and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in t
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for i
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE) today announced that members of management will participate at the following investor conferences. TD Cowen 45th Annual Health Care Conference Date: Tuesday, March 4, 2025Time: 2:30 p.m. ET Leerink Global Healthcare ConferenceDate: Tuesday, March 11, 2025Time: 8:40 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first patient has been dosed in the Part B portion of the Phas
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications.
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD SAN FRANCISCO and WALTHAM, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data up to 12 months reinforce APG777's best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing 16-week topline data from APG777 Phase 2 Part A trial in AD accelerated to mid-2025 based on strong enrollment Preclinical and coformulation proof-of-concept achieved for APG777 + APG990 combination Phase 1b head-to-head trial against DUPIXENT expected to initiate in 2025 with data in 2H 2026 Preclinical proof-of-concept achieved for APG7
Apogee Therapeutics Announces Agenda for Virtual R&D Day
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
Apogee Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage on Apogee Therapeutics with a new price target
Citigroup initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $95.00
Canaccord Genuity initiated coverage on Apogee Therapeutics with a new price target
Canaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00
BofA Securities initiated coverage on Apogee Therapeutics with a new price target
BofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00
BTIG Research initiated coverage on Apogee Therapeutics with a new price target
BTIG Research initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $43.00
TD Cowen initiated coverage on Apogee Therapeutics
TD Cowen initiated coverage of Apogee Therapeutics with a rating of Outperform
Wedbush initiated coverage on Apogee Therapeutics with a new price target
Wedbush initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $40.00
Guggenheim initiated coverage on Apogee Therapeutics with a new price target
Guggenheim initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00
Stifel initiated coverage on Apogee Therapeutics with a new price target
Stifel initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $34.00
Jefferies initiated coverage on Apogee Therapeutics with a new price target
Jefferies initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00
Apogee Therapeutics Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Apogee Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Chief Medical Officer Dambkowski Carl sold $48,463 worth of shares (1,590 units at $30.48), decreasing direct ownership by 0.63% to 251,033 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Executive Officer Henderson Michael Thomas sold $301,511 worth of shares (10,000 units at $30.15), decreasing direct ownership by 0.77% to 1,292,987 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Medical Officer Dambkowski Carl exercised 795 shares at a strike of $22.86 and sold $143,229 worth of shares (3,520 units at $40.69), decreasing direct ownership by 1% to 252,623 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Executive Officer Henderson Michael Thomas sold $608,700 worth of shares (15,000 units at $40.58), decreasing direct ownership by 1% to 1,302,987 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Executive Officer Henderson Michael Thomas exercised 8,500 shares at a strike of $22.86, increasing direct ownership by 0.65% to 1,317,987 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Executive Officer Henderson Michael Thomas sold $732,693 worth of shares (15,000 units at $48.85), decreasing direct ownership by 1% to 1,309,487 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Medical Officer Dambkowski Carl exercised 1,360 shares at a strike of $22.86 and sold $191,740 worth of shares (4,085 units at $46.94), decreasing direct ownership by 1% to 255,348 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Chief Medical Officer Dambkowski Carl exercised 1,815 shares at a strike of $22.86 and sold $221,363 worth of shares (4,540 units at $48.76), decreasing direct ownership by 1% to 258,073 units (SEC Form 4)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
SEC Form 4 filed by Chief Executive Officer Henderson Michael Thomas
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
Apogee Therapeutics Inc. SEC Filings
Apogee Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
SEC Form 144 filed by Apogee Therapeutics Inc.
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
Apogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
SEC Form S-8 filed by Apogee Therapeutics Inc.
S-8 - Apogee Therapeutics, Inc. (0001974640) (Filer)
SEC Form 10-K filed by Apogee Therapeutics Inc.
10-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
SEC Form SCHEDULE 13G filed by Apogee Therapeutics Inc.
SCHEDULE 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SEC Form 144 filed by Apogee Therapeutics Inc.
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
SEC Form 144 filed by Apogee Therapeutics Inc.
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
Apogee Therapeutics Inc. Leadership Updates
Live Leadership Updates
Apogee Therapeutics Announces Agenda for Virtual R&D Day
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger's over 30 years of experience in drug development,
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
SAN FRANCISCO and WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna's knowledge and successful track record in the I&I space as well as his significant development, commercial and executive management experience contributed to the Apogee board of directors' selection decision. "We are thrilled to welcome Mark as chair of our board and to
Apogee Therapeutics Inc. Financials
Live finance-specific insights
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for i
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance dosing of every 3- or 6-months Single dose showed deep and sustained inhibition of key atopic dermatitis biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available with inhibition still ongoing at time of data cut) APG777 was well tolerated with a favorable safety profile consistent with the anti-IL-13 class Company plans to initiate a randomized, placebo-controlled, 16-week Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis in 1H 2024 with induction r
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Apogee's website at https://investors.apogeeth
Apogee Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SEC Form SC 13G filed by Apogee Therapeutics Inc.
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SEC Form SC 13G filed by Apogee Therapeutics Inc.
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SEC Form SC 13D/A filed by Apogee Therapeutics Inc. (Amendment)
SC 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)